<DOC>
	<DOCNO>NCT00371124</DOCNO>
	<brief_summary>The purpose study find optimal dose atropine prevent rapid progression myopia child compare efficacy , safety functional impact binocular treatment 0.5 % , 0.1 % 0.01 % atropine develop treatment regimen routine management childhood myopia .</brief_summary>
	<brief_title>Safety Efficacy Study 0.5 % , 0.1 % &amp; 0.01 % Atropine Treatment Both Eyes In Treatment Myopia In Children</brief_title>
	<detailed_description>A Randomised , Double-Masked Study Compare The Safety Efficacy Bilateral 0.5 % , 0.1 % &amp; 0.01 % Atropine Treatment In Controlling Progression Myopia In Children Study Duration Visit Schedule Total 5 year 15 schedule visit . 1 . Phase I : 2 year 8 schedule visit 2 . Phase II : 3 year 7 schedule visit STUDY DESIGN This study consist 2 phase , different design . Phase I double-masked single-centre clinical trial wherein 400 child age 6-12 year , myopia -2.00 D bad eye , assent parental/guardian consent obtain , randomise receive 0.5 % atropine , 0.1 % atropine 0.01 % atropine nightly eye . Participants assign treatment ratio 2:2:1 , respectively . Each child receive treatment period 2 year review every 4 month . Phase II open-label study wherein child continue followed-up regularly change refractive error stop atropine treatment . Those child demonstrate myopia progression -0.5 D , least one eye minimum 8 month washout period restart atropine treatment eye . The appropriate dose determine analysis data Phase I study . Treatment 2 year child , include receive treatment , review every 6 month .</detailed_description>
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Atropine</mesh_term>
	<criteria>1 . Written Informed Consent parent assent child obtain 2 . Children age 6 12 year 3 . Refractive error spherical equivalent 2.00 D bad eye measure cycloplegic autorefraction 4 . Active myopia progression least spherical equivalent 0.50 D last 12 month determine suggest refractive record change lens power 5 . Astigmatism le equal 1.50 D measure cycloplegic noncycloplegic autorefraction 6 . Distance vision correctable logMAR 0.2 good eye 7 . A difference noncycloplegic subjective spherical refraction cycloplegic subjective spherical refraction great 1.00 D 8 . Normal intraocular pressure great 21 mmHg 9 . Normal ocular health myopia 10 . In good general health history cardiac significant respiratory diseases 11 . No asthmarequiring medication past one year 12 . No allergy atropine , cyclopentolate , proparacaine benzalkonium chloride 13 . Willing able comply schedule visit study procedures 1 . Ocular systemic disease may affect vision refractive error 2 . Any ocular condition wherein topical atropine contraindicate 3 . Defective binocular function stereopsis 4 . Amblyopia manifest strabismus include intermittent tropia 5 . Previous current use atropine pirenzepine 6 . Any condition preclude adherence protocol include unwillingness refrain contact lens wear duration study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Myopia treatment</keyword>
	<keyword>Atropine</keyword>
</DOC>